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Revascularization in Patients With Isolated
Proximal LAD Disease?We thank Dr. Matsoukis and colleages for their letter
expressing an interest in our recent study (1).
Regarding the type of drug-eluting stents (DES)
(ﬁrst vs. second generation), 72% of the stents used in
the propensity-matched DES/coronary artery bypass
graft (CABG) pairs were second-generation DES, with
the others being ﬁrst-generation DES. When the pairs
were limited to second-generation DES compared
with CABG surgery, there were still no signiﬁcant
differences for mortality or for mortality/myocardial
infarction/stroke. Repeat revascularization rates were
again lower for CABG surgery, and the adjusted haz-
ard ratio (AHR) was very similar to the AHR for all
pairs (0.60 vs. 0.54 for all pairs).
It is possible that our results could have been
different if we had used cardiac mortality instead of
all-cause mortality, but unfortunately we did not
have access to that measure.
It is not true that CABG surgery was associated
with a signiﬁcantly lower rate when we looked at the
composite endpoint of mortality/myocardial infarc-
tion/stroke. As the letter states, we found the AHR tobe 0.96 (95% conﬁdence interval: 0.86 to 1.06),
which is not signiﬁcant because the conﬁdence
interval includes the number 1.*Edward L. Hannan, PhD
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Compared Correctly With
Clopidogrel in Non–ST-
Segment Elevation Acute
Coronary Syndrome?We read with great interest the paper by Montalescot
et al. (1) and the editorial by Ibanez and Dangas (2)
about prasugrel in non–ST-segment myocardial in-
farction (NSTEMI), and we appreciate the research on
this interesting issue. The ACCOAST (A Comparison of
Prasugrel at PCI or Time of Diagnosis of Non-ST
Elevation Myocardial Infarction) trial demonstrated
that pre-treatment with prasugrel in NSTEMI adds no
beneﬁt compared with initiating the drug after angi-
ography and also was associated with an increase in
bleeding events (3). In the same way, in the subgroup
of patients analyzed in the ACCOAST-PCI, the results
are concordant with the main study in terms of same
clinical outcome as well as a higher rate of bleeding
events (1).
